NervGen Pharma Announces Public Offering of Shares and Warrants
NervGen Pharma has priced a public offering for the sale of 24 million common shares at $2.50 each, along with warrants to purchase an equal number of shares at $3.68 per share.
More World news
- Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target
- X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027
- Alvotech Shares Decline Following Third Quarter Earnings Miss
- Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth
- Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures
- DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance
- Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation
- Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation
- San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity
- Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations